Co-Diagnostics, Inc. (CODX) Spending and interest coverage
- R&D / revenue · 12 months: Value 2726.16%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 169.87%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2726.16% | Research and development expense / revenue. Period ending 2026-06-30. $19.67M ÷ $721.39K × 100 ≈ 2726.16% |
| Stock-based compensation / revenue · 12 months | 169.87% | Share-based compensation / revenue. Period ending 2026-06-30. $1.23M ÷ $721.39K × 100 ≈ 169.87% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 19.67M USD | Research and Development Expense |
| Revenue | 721.39K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 1.23M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -48.96M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.67M | $721.39K | $1.23M | $-48.96M | (m) | 2726.16% | 169.87% | (m) | (m) |
| 2026-03-31 | $20.20M | $718.17K | $1.59M | $-50.82M | (m) | 2812.90% | 221.67% | (m) | (m) |
| 2025-12-31 | $19.14M | $622.49K | $2.25M | $-50.17M | (m) | 3074.31% | 361.14% | (m) | (m) |
| 2025-09-30 | $18.85M | $507.89K | $3.27M | $-35.53M | (m) | 3710.45% | 644.73% | (m) | (m) |
| 2025-06-30 | $19.24M | $1.00M | $3.82M | $-38.75M | (m) | 1917.47% | 380.56% | (m) | (m) |
| 2025-03-31 | $20.17M | $3.50M | $4.74M | $-38.37M | (m) | 576.68% | 135.49% | (m) | (m) |
| 2024-12-31 | $20.98M | $3.92M | $5.43M | $-40.08M | (m) | 535.86% | 138.82% | (m) | (m) |
| 2024-09-30 | $22.35M | $7.32M | $5.94M | $-40.00M | (m) | 305.30% | 81.17% | (m) | (m) |
| 2024-06-30 | $23.26M | $9.14M | $7.07M | $-38.70M | (m) | 254.57% | 77.37% | (m) | (m) |
| 2024-03-31 | $23.63M | $6.68M | $7.74M | $-43.01M | (m) | 353.83% | 115.89% | (m) | (m) |
| 2023-12-31 | $22.96M | $6.81M | $8.34M | $-42.71M | (m) | 337.09% | 122.38% | (m) | (m) |
| 2023-09-30 | $21.52M | $4.66M | $8.92M | $-57.00M | (m) | 462.04% | 191.38% | (m) | (m) |
| 2023-06-30 | $20.77M | $7.30M | $8.97M | $-54.60M | (m) | 284.72% | 123.00% | (m) | (m) |
| 2023-03-31 | $18.68M | $12.12M | $8.34M | $-46.75M | (m) | 154.12% | 68.78% | (m) | (m) |
| 2022-12-31 | $17.44M | $34.22M | $7.54M | $-26.98M | (m) | 50.96% | 22.04% | (m) | (m) |
| 2022-09-30 | $14.88M | $53.22M | $6.80M | $9.45M | (m) | 27.96% | 12.77% | (m) | (m) |
| 2022-06-30 | $15.74M | $78.22M | $5.98M | $29.62M | (m) | 20.12% | 7.64% | (m) | (m) |
| 2022-03-31 | $16.52M | $100.56M | $5.37M | $45.55M | (m) | 16.42% | 5.34% | (m) | (m) |
| 2021-12-31 | $14.96M | $97.89M | $5.51M | $46.06M | (m) | 15.29% | 5.63% | (m) | (m) |
| 2021-09-30 | $13.89M | $104.63M | $4.42M | $51.79M | (m) | 13.28% | 4.23% | (m) | (m) |
| 2021-06-30 | $8.92M | $96.35M | $4.05M | $50.19M | (m) | 9.26% | 4.21% | (m) | (m) |
| 2021-03-31 | $5.00M | $93.03M | $3.82M | $53.11M | (m) | 5.38% | 4.10% | (m) | (m) |
| 2020-12-31 | $3.19M | $74.55M | $2.74M | $41.69M | (m) | 4.27% | 3.67% | (m) | (m) |
| 2020-09-30 | $2.45M | $47.52M | $2.69M | $24.04M | (m) | 5.16% | 5.65% | (m) | (m) |
| 2020-06-30 | $1.86M | $25.74M | $1.92M | $7.98M | (m) | 7.23% | 7.45% | (m) | (m) |
| 2020-03-31 | $1.42M | $1.76M | $1.43M | $-5.72M | (m) | 80.91% | 81.44% | (m) | (m) |
| 2019-12-31 | $1.37M | $214.97K | $1.09M | $-5.89M | (m) | 637.95% | 506.29% | (m) | (m) |
| 2019-09-30 | $1.37M | $117.23K | $1.33M | $-6.09M | (m) | 1165.52% | 1136.76% | (m) | (m) |
| 2019-06-30 | $1.37M | $85.49K | $1.55M | $-6.11M | (m) | 1597.49% | 1815.43% | (m) | (m) |
| 2019-03-31 | $1.41M | $33.62K | $1.40M | $-6.09M | (m) | 4197.66% | 4150.47% | (m) | (m) |
| 2018-12-31 | $1.36M | $39.91K | $1.33M | $-6.12M | (m) | 3410.47% | 3338.40% | (m) | (m) |
| 2018-09-30 | $1.27M | (m) | $1.93M | $-5.79M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $1.21M | (m) | $2.10M | $-5.93M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $1.03M | (m) | $2.05M | $-5.28M | $310.23K | (m) | (m) | -17.01× | Reported |
| 2017-12-31 | $1.00M | (m) | $2.03M | $-4.56M | $310.23K | (m) | (m) | -14.71× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $731.47K | (m) | $69.56K | $-1.69M | $240.72K | (m) | (m) | -7.01× | Reported |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |